EMA Authorised: Tecartus (autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel)) — Kite Pharma EU B.V.

View source ↗

Summary

The European Medicines Agency authorised Tecartus (brexucabtagene autoleucel) for mantle cell lymphoma with conditional approval, and it has orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Tecartus (brexucabtagene autoleucel)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Mantle-Cell. MAH: Kite Pharma EU B.V.. Decision date: 26/02/2026. Conditional approval. Orphan medicine